secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001193125-25-003214
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotech reports encouraging Phase 1 data: 50% tumor shrinkage (VIR-5818), 58% PSA50 (VIR-5500)
--------------------------------------------------------------------------------

- VIR-5818 (HER2): 50% (10/20) tumor shrinkage at doses ≥400 µg/kg; cPR in 33% (2/6) HER2+ CRC.
- VIR-5500 (PSMA mCRPC): PSA declines in 100% (12/12) and PSA50 response in 58% (7/12) at first dose ≥120 µg/kg.
- Safety: No dose-limiting CRS; max grade 2 CRS; MTD not reached for either TCE; dosing up to 1000 µg/kg.
- PRO-XTEN masking technology shows minimal systemic unmasking; half-life 6-10 days enabling Q3W dosing.
- Phase 1 trials ongoing; dose escalation continues; company to hold investor call Jan 8, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312525003214/0001193125-25-003214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312525003214/d887412d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-003214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer